Pharma News

Hyderabad, India and Princeton, NJ, USA Dr.Reddy’s Laboratories Ltd.(BSE: 500124, NSE:DRREDDY, NYSE: RDY) today announced the acquisition of an  eminent portfolio of over the counter (OTC) brands in the cough and cold, pain, and dermatology categories. The company acquired six OTC brands from Ducere Pharma, including DOAN’S®, BUFFERIN®, NUPERCAINAL® Ointment, CRUEX ® Nail  Gel, COMTREX ® , and MYOFLEX ®.

After Alzheimer's, Parkinson's disease (PD) is the leading neurodegenerative disorder, affecting close to a million Americans, with 50,000 new cases diagnosed every year. A progressive disorder of the nervous system affecting movement, PD typically strikes adults in mid-life. In many cases, the spread of the disease to other brain areas leads to Parkinson's disease dementia, characterized by deterioration of memory, reason, attention and planning.

In roughly one-third of pancreatic cancer patients, tumors have grown around the pancreas to encompass critical blood vessels. Conventional wisdom has long held that surgery to remove the tumors is rarely an option, and life expectancies are usually measured in months. Mayo Clinic, teaming oncologists, gastrointestinal and vascular surgeons and others, is finding that many of these patients actually are candidates for surgery. Mayo has been fine-tuning a protocol to treat them, and in two studies, found survival now stretching into years.

Scorpions, snakes, snails, frogs and other creatures are thought to produce tens or even hundreds of millions of distinct venoms. These venoms have been honed to strike specific targets in the body.

Allergan plc  announced that the Japanese Ministry of Health, Labour and Welfare has approved an additional use for BOTOX Vista® (Allergan's botulinum toxin type A product) as a treatment for crow's feet lines (CFL).

Avantis Medical Systems, Inc announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its Third Eye® Panoramic™ device for use as a resposable product for colonoscopies.  Previously cleared as a disposable device, this latest clearance now allows Third Eye Panoramic to be marketed in the U.S. as a resposable device that can be used multiple times prior to disposal.

[adsense:336x280:8701650588]

Egalet Corporation announced that it has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for OXAYDO® (oxycodone HCl, USP) tablets CII.

Zealand announces that the US Food and Drug Administration (FDA)  has made briefing documents on lixisenatide and the lixisenatide/Lantus® combination available on its website. The documents relate to the upcoming meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, scheduled by the FDA for 8:00 am to 5:00 pm ET on 25 May 2016 to discuss the New Drug Applications (NDAs) for the two drug products intended for the treatment of adults with Type 2 diabetes. The NDAs were submitted by Sanofi.

Astellas Pharma Inc., Daiichi Sankyo Company, Limited and Takeda Pharmaceutical Company Limited announced that they have entered into a joint research agreement. It is an agreement to comprehensively acquire and analyze fundamental biomarker data on healthy adult volunteers in order to optimize and accelerate the development of innovative medicines.